<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279499</url>
  </required_header>
  <id_info>
    <org_study_id>sevoflurane-propofol-obesity</org_study_id>
    <nct_id>NCT01279499</nct_id>
  </id_info>
  <brief_title>Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients</brief_title>
  <official_title>Propofol Versus Sevoflurane as Sole Anesthetic Agent in Gastric By-Pass Surgery for Morbid Obesity: A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <brief_summary>
    <textblock>
      The objective of this prospective randomized clinical study was to compare anesthesia, in
      morbidly obese patents (BMI &gt;50) who underwent BPD-RYGBP with either sevoflurane or propofol
      with remifentanyl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective double blind randomized controlled trial. The patients will be assigned
      to one of 4 groups (gr): (1) SEVO group, guided by a target end tidal concentration 1 - 2 MAC
      and modified according to the haemodynamics (BP, HR) of the patients using a bolus inhalation
      (4 MAC), (2) SEVO-BIS group, using SEVO to a target BIS of 40 - 50, (3) PROPO-REMI and (4)
      PROPO-REMI-BIS groups accordingly. In groups 1 and 2, anaesthesia will be induced with IV
      PROPO (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]),
      REMI (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). In groups 3, 4 anaesthesia will be
      induced with a continuous IV PROPO infusion (21mg/kg TW/h for 5 min, 12 mg/kg TW/h for 10 min
      and then 6 mg/kg TW/h), followed by an IV bolus of REMI and succinylcholine as above. Every
      rise of BP or HR &gt; 15% of baseline will be followed by a bolus SEVO inhalation in grs 1 and 2
      or REMI bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of REMI from 0.1
      to 1.0 μg/kg/min in groups 3 and 4. An epidural catheter will be placed prior to induction
      for postoperative analgesia only. Intraoperative BP and HR, anaesthetic consumption, recovery
      scores (Aldrete, Chung, White) and anaesthesia cost will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of perioperative haemodynamic measurements (HR, MAP), recovery scores (Aldrete, White,Chung)</measure>
    <time_frame>5 min after induction, 1 hour after induction, end of the surgery, 2 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Consumption, Drug Cost.</measure>
    <time_frame>End of the surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>SEVO group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR &gt; 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR &lt; 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR &gt; 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEVO-BIS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR &gt; 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR &lt; 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR &gt; 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propo- Remi group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).
Every rise of BP or HR &gt; 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR &lt; 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR &gt; 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propo-Remi-BIS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).
The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is &gt; 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR &lt; 70/ min, Nifedipine 10 mg will be given s.l. and if HR &gt; 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR &gt; 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes</description>
    <arm_group_label>SEVO group</arm_group_label>
    <other_name>Sevoflurane , Abbott</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.</description>
    <arm_group_label>SEVO-BIS group</arm_group_label>
    <other_name>Sevoflurane, Abbott and BIS, Aspect Medical Systems, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol- Remifentanyl</intervention_name>
    <description>Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).
Every rise of BP or HR &gt; 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min</description>
    <arm_group_label>Propo- Remi group</arm_group_label>
    <other_name>Propofol, Diprivan, Fresenius</other_name>
    <other_name>Remifentanyl, Ultiva, GlaxoSmithKline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol, Remifentanyl</intervention_name>
    <description>Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).
The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR &gt; 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min</description>
    <arm_group_label>Propo-Remi-BIS group</arm_group_label>
    <other_name>Propofol, Fresenius, BIS, Aspect Medical Systems, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 yrs

          -  BMI&gt;50 kg/m2

          -  Written consent for the participation in the study

        Exclusion Criteria:

          -  History of significant cardiac disease, (aortic stenosis, angina, CHF or previous
             cardiac or intrathoracic operations)

          -  Significant renal dysfunction (serum creatinine&gt;1.8 mg/dl)

          -  Significant liver dysfunction (evidenced by abnormal LFTs)

          -  History of hyper or hypothyroidism

          -  History of psychiatric or neurologic disorders

          -  Recall during general anesthesia

          -  Substance abuse (alcohol or other drugs)

          -  Counter-indications of placement of thoracic epidural catheter( previous spine surgery
             or coagulation abnormalities )

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athina Siampalioth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Patras, Departement of Anesthesiology and Critical Care Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kriton Filos, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Patras, Departement of Anesthesiology and Critical Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kriton Filos, Professor,MD, PhD</last_name>
    <phone>00302610999341</phone>
    <email>kritonfilos@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Athina Siampalioti, MD</last_name>
    <phone>6944678681</phone>
    <email>atenaba@in.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Patras, Departement of Anesthesiology and Critical Care Medicine</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kriton Filos, Professor</last_name>
      <phone>00302610999341</phone>
      <email>kritonfilos@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kriton Filos</name_title>
    <organization>University of Patras, Departement of Anesthesiology and Critical Care Medicine</organization>
  </responsible_party>
  <keyword>Morbid obesity</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Propofol</keyword>
  <keyword>Remifentanyl</keyword>
  <keyword>BIS</keyword>
  <keyword>Cardiovascular stability</keyword>
  <keyword>Recovery scores</keyword>
  <keyword>Drug consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

